ArticleMaterials today. Bio2025
Biocompatible cloaking of bacteria for effective tumor imaging and therapy.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- ROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment.Drug delivery · 2026Article
- Engineered bacteria as exogenous organelle mimics restore PTEN and p53 tumor suppressor functions for cancer therapy.Nature communications · 2026Article
- Prodrug-integrated multifunctional liposome encapsulation enhances probiotic-based bacteriotherapy for inflammatory bowel disease.Materials today. Bio · 2026Article
- The challenges and strategies for navigatingTheranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria possess distinctive characteristics, such as tropism, motility, and genetic editability, which make them highly attractive for biomedical applications, such as tumor imaging and therapy. However, the immunogenicity triggered by endotoxins may lead to severe adverse effects and prompt quick elimination in the body, thus restricting their clinical applications. In this study, we described a double-layer coating technique employing tannic acid (TA) and albumin (BSA) for bacteria encapsulation. This compact coating effectively shields endotoxin exposure and inhibits endotoxin leakage from bacteria, exhibiting a favorable safety profile. Moreover, bacteria coated with BSA have superior biocompatibility with their surroundings, which prevents phagocytes from eliminating the bacteria, hence prolonging the reservation in vivo. As bacteria grow, the BSA-TA layer progressively detaches after reaching targeted sites, allowing free bacteria to exploit their own advantages. Importantly, the BSA-TA coating strategy protects bacteria against various environmental assaults without compromising their growth, proliferation, or motility, maintaining their inherent characteristics. In murine tumor models, the BSA-TA-coated bacteria demonstrated enhanced long-term tumor imaging and therapeutic efficacy against tumors. Together, the BSA-TA coating strategy improves the biocompatibility of bacteria and has the capacity to expand the range of bacteria for biomedical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.